- High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder; LXRP sees more licensing opportunities in 2018
- LXRP’s technology is patented in the U.S. and Australia; company has national/regional filings pending in 44 countries
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) generates revenue by out-licensing its patented global technology related to ingestion of edible cannabinoids at a rate of 5-10% of gross sales to its third-party partners. LXRP has also expanded its process of improved and faster inhalation by the body of fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) in pain medications, and even nicotine, a good example of bioabsorption breakthrough technology (http://cnw.fm/DnHZ9). LXRP is now positioned to license its technology to tobacco giants and major drug companies, as well as cannabinoid biopharmaceutical companies.
As a result, LXRP sees new business opportunities in 2018. The company is now positioned to out-license — at a high royalty rate — its intellectual property (IP) to biopharmaceutical companies as a partner rather than a competitor, working with other companies, including cannabinoid edible producers, instead of competing with them.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer